Lilly Takes Seven in Ten Medicare Bridge Patients as GLP-1 Guidance Rises Again

Eli Lilly reported third-quarter results on October 29 that beat expectations on nearly every line: revenue of $24.4 billion, up 39%, and full-year guidance raised to $91 to $92 billion. Inside the numbers was a more strategic detail: roughly seven in ten patients using the new Medicare GLP-1 Bridge program are on a Lilly medicine, and most of them are new to this class of drugs entirely. [1][2]

The quarter behind the raise

Lilly's third-quarter revenue reached $24.4 billion, up 39% from a year earlier, driven primarily by Mounjaro for diabetes at $10.7 billion (up 65%) and Zepbound for obesity at $5.4 billion (up 49%). The company raised its full-year revenue guidance to a range of $91 to $92 billion, from $85 to $87 billion, a $5.5 billion increase at the midpoint. [1]

The shape of the growth matters as much as the size. In the U.S., volume rose 41% while realized prices fell 7%, a decline Lilly attributed primarily to Zepbound. [1]

The Bridge channel

Since the summer launch of the GLP-1 Bridge program for Medicare Part D patients, Lilly executives have pointed to it as an access advantage over Novo Nordisk. On Thursday's earnings call, U.S. president Ilya Yuffa said roughly "seven out of 10" older adults participating in the program are using a Lilly medicine. [2][3]

Two more details Yuffa shared on the call stand out. About 75% of patients entering the program are choosing injectables rather than the new oral options, and about 80% of patients using the Bridge are new to incretin therapies altogether, first-time patients entering the category through a national coverage channel. [2]

Lilly's oral entry, Foundayo, generated $184 million in its first full quarter on the market, below some analyst expectations, though Yuffa said the company's share of new U.S. oral obesity prescriptions is approaching "four out of 10." [1][2]

What it signals

Lilly's CEO David Ricks credited "expanded U.S. coverage for obesity care" alongside consumer demand for the quarter. The company is growing volume faster than price, raising guidance by billions, and capturing the large majority of a federal access channel that is only months old, while a retail chain builds support services around the same program, as Walgreens did in its own announcement earlier this week. [1][2]

The growth is real, the realized price of Zepbound is falling, and the newest patients are arriving through national channels.

What it means for a clinic: Four out of five patients entering the Medicare Bridge have never been on an incretin therapy. They are meeting this category for the first time through a coverage program and, increasingly, through the retail and manufacturer services built around it. Falling realized prices will not be the competitive problem for clinics; being absent from the patient's first contact with the category will. The durable answer remains what a national channel cannot offer: a named clinician, continuity over years, and support that survives a formulary change. Say that plainly to patients who now see GLP-1 access advertised everywhere.